4D Molecular Therapeutics (FDMT) Enterprise Value (2019 - 2025)
Historic Enterprise Value for 4D Molecular Therapeutics (FDMT) over the last 7 years, with Q3 2025 value amounting to -$305.1 million.
- 4D Molecular Therapeutics' Enterprise Value rose 3921.74% to -$305.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$305.1 million, marking a year-over-year increase of 3921.74%. This contributed to the annual value of -$424.9 million for FY2024, which is 4740.8% down from last year.
- Latest data reveals that 4D Molecular Therapeutics reported Enterprise Value of -$305.1 million as of Q3 2025, which was up 3921.74% from -$293.2 million recorded in Q2 2025.
- In the past 5 years, 4D Molecular Therapeutics' Enterprise Value ranged from a high of -$161.7 million in Q3 2021 and a low of -$541.9 million during Q2 2024
- Its 5-year average for Enterprise Value is -$308.7 million, with a median of -$288.2 million in 2023.
- In the last 5 years, 4D Molecular Therapeutics' Enterprise Value plummeted by 16235.99% in 2024 and then soared by 4589.41% in 2025.
- Over the past 5 years, 4D Molecular Therapeutics' Enterprise Value (Quarter) stood at -$247.8 million in 2021, then rose by 13.81% to -$213.6 million in 2022, then plummeted by 34.97% to -$288.2 million in 2023, then tumbled by 47.41% to -$424.9 million in 2024, then grew by 28.2% to -$305.1 million in 2025.
- Its Enterprise Value stands at -$305.1 million for Q3 2025, versus -$293.2 million for Q2 2025 and -$321.4 million for Q1 2025.